Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
For full access to this article login to GEN Select now.
Ramping Up Effort for Improving Kinase Assays
Firms Use Myriad Strategies to Identify and Characterize Kinase Inhibitors
- Protein kinases are at the forefront of drug discovery, representing the largest druggable class of compounds for the pharmaceutical industry with 518 kinases associated with approximately 400 diseases. There are many approaches to measure kinase activity in order to identify and characterize kinase inhibitors. The nature of kinases ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.